“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Sunday, August 31, 2025

Dyax Corp


Dyax Corp products


K

  • Kalbitor®

    • Generic Name: ecallantide

    • Indication: Treatment of acute attacks of hereditary angioedema (HAE) in patients aged 12 years and older. Delivered via subcutaneous injections.

R

  • Ramucirumab (marketed as Cyramza® by Eli Lilly)

    • Indication: Oncology—used for gastric, lung, colorectal cancers, and other malignancies. Dyax receives royalties on sales but does not market the product directly.

D

  • DX-2930 (Lanadelumab)

    • Status: Investigational (pre-approval at Dyax)

    • Indication: Long-term prophylaxis for hereditary angioedema (HAE); administered to reduce attack frequency via monoclonal antibody targeting plasma kallikrein.



on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)